Acquisition of Spyre and concurrent oversubscribed $210M private investment positions the company to advance a world-class inflammatory bowel disease (IBD) portfolio.
Latest News from Aeglea
Latest News from Aeglea
Get In Touch With Us

Acquisition of Spyre and concurrent oversubscribed $210M private investment positions the company to advance a world-class inflammatory bowel disease (IBD) portfolio.